Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from BerGenBio ASA ( (BRRGF) ) is now available.
BerGenBio ASA and Oncoinvent ASA are set to merge through a statutory triangular merger, with completion expected on 29 October 2025. The merger will result in BerGenBio changing its name to Oncoinvent ASA and continuing its listing on the Oslo Stock Exchange under the ticker ‘ONCIN’. This strategic move aims to consolidate their market presence and enhance their operational capabilities in the biotechnology sector.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
Oncoinvent is a clinical-stage biotechnology company focused on developing novel radiopharmaceutical therapies for cancer treatment. Their lead product, Radspherin®, targets micro-metastases post-surgery using radium-224, and is currently undergoing clinical trials in the US, UK, and Europe.
Average Trading Volume: 85,475
Current Market Cap: NOK46.9M
For detailed information about BRRGF stock, go to TipRanks’ Stock Analysis page.